C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
12/2004
12/23/2004	US20040259081 Method for protein expression starting from stabilized linear short DNA in cell-free in vitro transcription/translation systems with exonuclease-containing lysates or in a cellular system containing exonucleases
12/23/2004	US20040258709 Hepatitis B virus polypeptides
12/23/2004	US20040258708 Cytotoxic T-cell epitopes of papillomavirus L1 protein and their use in diagnostics and therapy
12/23/2004	US20040258707 Nucleotide sequences encoding the structural proteins (causative agent) which consists of a basic capsid protein, three envelope proteins designated as E1, E2 and E3, and a 6K protein; stable DNA vaccines and vector vaccines of live attenuated modified bacteria or virus; kits for medical diagnosis
12/23/2004	US20040258704 Bovine lactation associated immunotropic protein (CD14), encoding gene and application in B cell activation
12/23/2004	US20040258699 Treating an animal infected with Bacillus anthracis by administering an antibody or antibody fragment having binding affinity to the protective antigen of Bacillus anthracis and the ability to block binding of the protective antigen to cell receptors, edema factor and lethal factor; vaccines
12/23/2004	US20040258694 Hepatitis C receptor protein CD81
12/23/2004	US20040258691 Treating psoriasis in a patient by administering a therapeutically effective amount of an antibody immunospecific for vetronectin receptor av beta 3; antiinflammatory agents; antibody does not immunoreact with integrins other than av beta 3; cell adhesion
12/23/2004	US20040258689 Augmenting activin induced signaling in cells; screening for complex inhibitors; treatment of reproductive, developmental, skin, bone, hepatic, hematopoietic and/or central nervous system disorders; prostrate cancer
12/23/2004	US20040258688 Long lasting immunity using single dose at low concentration; exposing dendritic cells to antigen-antibody-DEC-205 receptor conjugate or to recombinant anti-DEC-205 antibody and promoting maturation
12/23/2004	US20040258686 Mammalian receptor proteins; related reagents and methods
12/23/2004	US20040258683 Administering epitope that maintains sustained reduction of circulating anti-dsDNA antibodies; reducing risk of renal flare
12/23/2004	US20040258682 Monoclonal antibody or fragment engineered in non-Fc constant heavy or light region; immunoconjugates for cancer diagnosis and therapy
12/23/2004	US20040258678 Isolated nucleic acid having high identity to sequence 215; vectors, host cells, antibodies
12/23/2004	US20040258675 Novel mutated form of arginine deiminase
12/23/2004	US20040258671 Delivering antiinflammatory cytokines to nervous system using gene therapy techniques
12/23/2004	US20040258668 Using nonsteroidal antiinflammatory drugs and/or muscle relaxants; supressing cytotoxicity during gene therapy
12/23/2004	US20040258667 Herpes simplex virus expressing foreign genes and method for treating cancers therewith
12/23/2004	US20040258666 Injecting adeno-associated virus vectors into central nervous system; transducing cells located at distal site for translation of biologically active molecule and expression; Niemann-Pick A disease
12/23/2004	US20040258665 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
12/23/2004	US20040258660 Tumor necrosis factor alpha analogues having three dimensional structure of similar to proteins from which they are derived; facilitating correct folding
12/23/2004	US20040258659 Design and/or selection of phage agonists or antagonists towards G protein coupled receptor ligands; enhanced anti-HIV-1 activity compared to RANTES
12/23/2004	US20040258656 Identified via SELEX method; phosphate-containing ligand is conjugated to polyoxyethylene glycol; transforming growth factor (TGF); pharmacokinetics
12/23/2004	US20040258616 Compositions and methods for treating cancer using IGSF9 and LIV-1
12/23/2004	US20040258568 Thermostated block with heat-regulating devices
12/23/2004	US20040256229 Subjecting nucleic acids to electrophoresis through the first portion of a matrix (preferably a random, linear copolymer of acrylamide) at at least 80 degrees C; deliberately cooling a second matrix portion to less than 30 degrees C.; and allowing the acids to migrate through the 2nd portion from the 1st
12/23/2004	DE10325814A1 Sichere Erzeugung eines gewünschten Produkts in hybriden Samen Secure production of a desired product in hybrid seed
12/23/2004	DE10324997A1 Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden MRP8 / MRP14 inhibitors and their use for the prevention and / or treatment of hypertrophic scars and keloids
12/23/2004	DE10322134A1 New nucleic acids, and encoded proteins, from prostatic cancer tissue, useful for diagnosis, treatment and in screening for specific binding agents
12/23/2004	DE10235248B4 Fusionsprotein mit verstärkter in vivo-Aktivität von Erythropoietin Fusion protein with enhanced in vivo activity of erythropoietin
12/23/2004	DE102004003595A1 Substrat zur Immobilisierung von physiologischem Material und Verfahren zu dessen Herstellung Substrate for the immobilization of physiological material and process for its preparation
12/23/2004	CA2570068A1 Methods for preparation of a library of submegabase resolution tiling pools and uses thereof
12/23/2004	CA2530972A1 Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
12/23/2004	CA2529828A1 Factor vii or viia gla domain variants
12/23/2004	CA2529366A1 Means and method for the detection of target nucleotide sequences using ligation assays with improved oligonucleotide probe pairs
12/23/2004	CA2528958A1 Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same
12/23/2004	CA2528948A1 Mutants of core 2 b-1,6-n-acetylglycosaminyltransferase
12/23/2004	CA2528741A1 Methods for the production of insulin in plants
12/23/2004	CA2528427A1 Modified human acid sphingomyelinase having increased activity, and methods for making the same
12/23/2004	CA2528425A1 Method for the microbiological isomerisation of alpha-hydroxy carboxylic acids
12/23/2004	CA2528418A1 Method to increase protein production in culture
12/23/2004	CA2528012A1 Methods and compositions for controlling efficacy of rna silencing
12/23/2004	CA2527954A1 Modified fiber proteins for efficient receptor binding
12/23/2004	CA2527863A1 Cell surface protein associated with human chronic lymphocytic leukemia
12/23/2004	CA2527843A1 Immunotherapeutics for biodefense
12/23/2004	CA2527361A1 Novel modified corin molecules having substitute activation sequences and uses thereof
12/23/2004	CA2526974A1 Proteases
12/23/2004	CA2526806A1 Proteases
12/23/2004	CA2526169A1 Fusion proteins
12/23/2004	CA2525784A1 Proteoglycan degrading mutants for treatment of cns
12/23/2004	CA2525584A1 Transgenic animal having an amyloid precursor protein with a modified beta secretase cleavage site
12/23/2004	CA2525017A1 Needleless syringe having medical agent accommodated therein
12/23/2004	CA2524325A1 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
12/23/2004	CA2521508A1 Methods for identification of coronaviruses
12/23/2004	CA2518646A1 Gdc-2 genes conferring herbicide resistance
12/23/2004	CA2515369A1 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
12/23/2004	CA2433141A1 Process for improving efficiency of dna amplification reaction
12/22/2004	EP1489417A1 Test piece for analyzing substance with biological origin, process for producing the same and method of examining test piece for substance with biological origin
12/22/2004	EP1489190A2 Fluorimetric detection system of a nucleic acid
12/22/2004	EP1489185A1 Methods and compositions for use in splicesome mediated rna trans-splicing
12/22/2004	EP1489184A1 Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
12/22/2004	EP1489183A1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
12/22/2004	EP1489182A1 Gene participating in acetic acid tolerance, acetic acid bacterium bred using the gene, and process for producing vinegar with the use of the acetic acid bacterium
12/22/2004	EP1489181A1 Dna and vector for regulating the expression of lachrymator synthase gene, method of regulating the expression of lachrymator synthase gene using the same, and plant with the regulated expression of lachrymator synthase gene
12/22/2004	EP1489180A1 P18abeta rp gene and p18abeta rp protein, novel gene/protein (p60trp) interacting therewith to inhibit cell death and cell death promoter
12/22/2004	EP1489179A1 Antiopoietin-related growth factor
12/22/2004	EP1489178A1 Polypeptides binding to human syntaxin 1a
12/22/2004	EP1489177A1 Cdc7-ask kinase complex, substrate of the kinase complex, antibody specific to the substrate, and method of screening compound capable of inhibiting cdc7-ask kinase using the same
12/22/2004	EP1489176A1 Fluorescent protein
12/22/2004	EP1489175A1 Modified promoter
12/22/2004	EP1489174A1 Method of modifying protein properties
12/22/2004	EP1489173A1 Candida utilis containing gamma-glutamylcysteine
12/22/2004	EP1489171A1 Functional molecule and process for producing the same
12/22/2004	EP1489170A1 Transporter selectively transporting sulfate conjugate and its gene
12/22/2004	EP1489169A1 Sumo inhibitors
12/22/2004	EP1489166A1 Amino acid racemase having low substrate specificity and process for producing racemic amino acid
12/22/2004	EP1489165A1 Recombinant fowlpox vaccine for protection against marek's disease
12/22/2004	EP1489164A1 Recombinant vaccinia viruses with modified F3 genes, uses thereof
12/22/2004	EP1489100A2 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
12/22/2004	EP1489099A2 Antibodies that bind the CD40CR receptor
12/22/2004	EP1489097A1 Inhibitors of human plasmin derived from kunitz domains and nucleic acids encoding the same
12/22/2004	EP1489095A1 Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
12/22/2004	EP1489094A1 Nuclear receptor rxr alpha isoforms
12/22/2004	EP1489093A1 Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer
12/22/2004	EP1489092A1 Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
12/22/2004	EP1488852A1 Method for manufacturing a microarray and verifying its quality
12/22/2004	EP1488805A2 CD28 pathway immunoregulation
12/22/2004	EP1488799A2 Soluble lymphotosin-Beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
12/22/2004	EP1488241A1 Arrays
12/22/2004	EP1488239A2 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
12/22/2004	EP1488231A2 Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
12/22/2004	EP1488011A2 Method of isolating binding peptides from a combinatorial phage display library and peptides produced thereby
12/22/2004	EP1488010A2 Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
12/22/2004	EP1488008A1 Method and devices for dna methylation analysis
12/22/2004	EP1488007A1 Gene expression profiling in biopsied tumor tissues
12/22/2004	EP1488006A2 Microcapsules with controlable permeability encapsulating a nucleic acid amplification reaction mixture and their use as reaction compartments for parallels reactions
12/22/2004	EP1488005A1 Histone deacetylase: novel molecular target of neurotoxicity
12/22/2004	EP1488004A2 Method of concentrating macromolecules or agglomerates of molecules or particles
12/22/2004	EP1488001A2 METHODS FOR GENERATING DOUBLE STRANDED DNA COMPRISING A 3’ SINGLE STRANDED PORTION AND USES OF THESE COMPLEXES FOR RECOMBINATION
12/22/2004	EP1487998A2 Methods for diagnosing and treating schizophrenia

1 ... 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 ... 4023